Article

Clinically relevant pulse-treatment generates bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax

2022-02-02

Abstract excerpt

Proteasome inhibitors bortezomib and carfilzomib are the backbone of treatments of multiple myeloma, which remains uncurable despite many recent advances. With many patients relapsing despite high initial response rates to proteasome inhibitor-containing regimens, it is critical to understand the process of acquired resistance. In vitro generated resistant cell lines are important tools in this process. The majori...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e3e7f6b0-1dad-5350-b105-59a5c4381532
DOI: 10.21203/rs.3.rs-1304383/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Clinically relevant pulse-treatment generates bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclaxDOI 10.21203/rs.3.rs-1304383/v1Read

A clinically relevant pulse treatment generates a bortezomib-resistant myeloma cell line that lacks proteasome mutations and is sensitive to Bcl-2 inhibitor venetoclax.Semantic proximity Read

Overcoming bortezomib resistance in multiple myelomaSemantic proximity Read

Different Strategies to Overcome Resistance to Proteasome Inhibitors—A Summary 20 Years after Their IntroductionSemantic proximity Read

Updates to the drug‐resistant mechanism of proteasome inhibitors in multiple myelomaSemantic proximity Read

Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myelomaSemantic proximity Read

Bortezomib-resistant myeloma cell lines: a role for mutated PSMB5 in preventing the accumulation of unfolded proteins and fatal ER stress.Semantic proximity Read

Targeting Bcl-2 for the treatment of multiple myeloma.Semantic proximity Read

Molecular Mechanisms of Bortezomib Resistant Adenocarcinoma CellsSemantic proximity Read

Ibrutinib inhibits BTK-driven NF-κB p65 activity to overcome bortezomib-resistance in multiple myelomaSemantic proximity Read

Dual targeting of BCL2 and MCL1 rescues myeloma cells resistant to BCL2 and MCL1 inhibitors associated with the formation of BAX/BAK hetero-complexesSemantic proximity Read

Modulating proteasome inhibitor tolerance in multiple myeloma: an alternative strategy to reverse inevitable resistanceSemantic proximity Read

Molecular Mechanisms of Acquired Proteasome Inhibitor ResistanceSemantic proximity Read